Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Licenses Preeclampsia Biomarker Panel from Mount Sinai

NEW YORK (GenomeWeb News) – Diagnostics developer Miraculins has agreed to license a panel of biomarkers from Mount Sinai Hospital that it will use to develop diagnostic assays to detect preecleampsia, the company said today.
These markers have shown evidence that they may help to diagnose the disease in its earliest stages, Winnipeg, Manitoba-based Miraculins said.
Preeclampsia affects 3 million expectant mothers worldwide every year and it is associated with premature births and infant illnesses such as cerebral palsy, blindness, epilepsy, deafness, lung conditions, and in severe cases it can cause death.
If the markers are developed into a reliable prenatal screen that is used for all pregnant women, it would have a potential US market of as many as 6.4 million women each year, said Miraculins.
The biomarker technology involved in the agreement was discovered through research by doctors at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, which is affiliated with the University of Toronto, and at the Hospital for Sick Children in Toronto.
"Our goal is to develop a diagnostic test so that physicians don't have to rely on symptoms alone to determine if a patient has preeclampsia,” Samuel Lunenfeld researcher Isabella Caniggia said in a statement.
Miraculins Director of Research and Development Stephen Frost said the company plans to immediately “begin executing an aggressive development plan with the objective of helping millions of women around the world at risk from this potentially fatal condition."
Financial terms of the agreement were not released.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.